CN116327830A - Traditional Chinese medicine composition for resisting oxidization and regulating intestinal flora and preparation method thereof - Google Patents
Traditional Chinese medicine composition for resisting oxidization and regulating intestinal flora and preparation method thereof Download PDFInfo
- Publication number
- CN116327830A CN116327830A CN202310493293.0A CN202310493293A CN116327830A CN 116327830 A CN116327830 A CN 116327830A CN 202310493293 A CN202310493293 A CN 202310493293A CN 116327830 A CN116327830 A CN 116327830A
- Authority
- CN
- China
- Prior art keywords
- ethanol solution
- intestinal flora
- chinese medicine
- traditional chinese
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 51
- 230000000968 intestinal effect Effects 0.000 title claims abstract description 33
- 239000003814 drug Substances 0.000 title claims abstract description 24
- 230000001105 regulatory effect Effects 0.000 title claims abstract description 23
- 238000007254 oxidation reaction Methods 0.000 title claims abstract description 14
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 240000000275 Persicaria hydropiper Species 0.000 claims abstract description 24
- 235000017337 Persicaria hydropiper Nutrition 0.000 claims abstract description 24
- 241000037740 Coptis chinensis Species 0.000 claims abstract description 20
- 230000003647 oxidation Effects 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 58
- 239000000284 extract Substances 0.000 claims description 27
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 239000011347 resin Substances 0.000 claims description 20
- 229920005989 resin Polymers 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 239000000843 powder Substances 0.000 claims description 14
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 238000004821 distillation Methods 0.000 claims description 7
- 238000002791 soaking Methods 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 6
- 239000003208 petroleum Substances 0.000 claims description 6
- 238000010298 pulverizing process Methods 0.000 claims description 6
- 241000218202 Coptis Species 0.000 claims description 5
- 235000002991 Coptis groenlandica Nutrition 0.000 claims description 5
- 239000003963 antioxidant agent Substances 0.000 claims description 5
- 230000003078 antioxidant effect Effects 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 5
- 239000004793 Polystyrene Substances 0.000 claims description 4
- 229920002223 polystyrene Polymers 0.000 claims description 4
- 239000002904 solvent Substances 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 2
- 241000186660 Lactobacillus Species 0.000 abstract description 19
- 229940039696 lactobacillus Drugs 0.000 abstract description 19
- 244000005709 gut microbiome Species 0.000 abstract description 18
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 abstract description 9
- 239000002207 metabolite Substances 0.000 abstract description 8
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 abstract description 5
- 239000003270 steroid hormone Substances 0.000 abstract description 4
- 241000193830 Bacillus <bacterium> Species 0.000 abstract description 2
- 241000736262 Microbiota Species 0.000 abstract description 2
- 239000006041 probiotic Substances 0.000 abstract description 2
- 235000018291 probiotics Nutrition 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 25
- 230000000694 effects Effects 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 9
- 241000700159 Rattus Species 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 101150086731 ges-1 gene Proteins 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 238000012163 sequencing technique Methods 0.000 description 6
- 229960004441 tyrosine Drugs 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000037353 metabolic pathway Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000002550 fecal effect Effects 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 238000000465 moulding Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000011550 stock solution Substances 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- WQZGKKKJIJFFOK-SVZMEOIVSA-N (+)-Galactose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-SVZMEOIVSA-N 0.000 description 2
- LCZBQMKVFQNSJR-UJPCIWJBSA-N 21-deoxycortisol Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)C[C@@H]2O LCZBQMKVFQNSJR-UJPCIWJBSA-N 0.000 description 2
- ACSFOIGNUQUIGE-AIPUTVCKSA-N 5beta-dihydrocortisol Chemical compound C1C(=O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 ACSFOIGNUQUIGE-AIPUTVCKSA-N 0.000 description 2
- 241001019659 Acremonium <Plectosphaerellaceae> Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000192125 Firmicutes Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000003698 anagen phase Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000021164 cell adhesion Effects 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 208000037887 cell injury Diseases 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000009545 invasion Effects 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- AODPIQQILQLWGS-UHFFFAOYSA-N (3alpa,5beta,11beta,17alphaOH)-form-3,11,17,21-Tetrahydroxypregnan-20-one, Natural products C1C(O)CCC2(C)C3C(O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 AODPIQQILQLWGS-UHFFFAOYSA-N 0.000 description 1
- SYGWGHVTLUBCEM-UHFFFAOYSA-N (3alpha,5alpha,17alphaOH)-3,17,21-Trihydroxypregnane-11,20-dione Natural products C1C(O)CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC21 SYGWGHVTLUBCEM-UHFFFAOYSA-N 0.000 description 1
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 1
- 108020004465 16S ribosomal RNA Proteins 0.000 description 1
- MOIQRAOBRXUWGN-WPWXJNKXSA-N 21-hydroxypregnenolone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)C(=O)CO)[C@@H]4[C@@H]3CC=C21 MOIQRAOBRXUWGN-WPWXJNKXSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 241000702460 Akkermansia Species 0.000 description 1
- 241000521092 Alloprevotella Species 0.000 description 1
- 241000606125 Bacteroides Species 0.000 description 1
- 239000004380 Cholic acid Substances 0.000 description 1
- 208000037384 Clostridium Infections Diseases 0.000 description 1
- 206010009657 Clostridium difficile colitis Diseases 0.000 description 1
- 206010054236 Clostridium difficile infection Diseases 0.000 description 1
- 239000009513 Coptidis rhizoma extract Substances 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000186871 Lactobacillus murinus Species 0.000 description 1
- 241000186604 Lactobacillus reuteri Species 0.000 description 1
- 241000869429 Muribaculaceae Species 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 238000010632 SOD assay Methods 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- SYGWGHVTLUBCEM-ZIZPXRJBSA-N Urocortisone Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 SYGWGHVTLUBCEM-ZIZPXRJBSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 1
- 229960002471 cholic acid Drugs 0.000 description 1
- 235000019416 cholic acid Nutrition 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000007412 host metabolism Effects 0.000 description 1
- 230000004179 hypothalamic–pituitary–adrenal axis Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000005027 intestinal barrier Anatomy 0.000 description 1
- 230000007358 intestinal barrier function Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000004938 stress stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- AODPIQQILQLWGS-GXBDJPPSSA-N tetrahydrocortisol Chemical compound C1[C@H](O)CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CC[C@@H]21 AODPIQQILQLWGS-GXBDJPPSSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 150000003668 tyrosines Chemical class 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 210000002417 xiphoid bone Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/70—Polygonaceae (Buckwheat family), e.g. spineflower or dock
- A61K36/704—Polygonum, e.g. knotweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/31—Extraction of the material involving untreated material, e.g. fruit juice or sap obtained from fresh plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a preparation method of a traditional Chinese medicine composition for resisting oxidation and regulating intestinal flora, which comprises polygonum hydropiper and coptis chinensis in a mass ratio of 1.8-2.2:1, wherein effective parts of the polygonum hydropiper and the coptis chinensis are extracted by a specific preparation method, the structures and compositions of the intestinal microbiota are obviously changed after the polygonum hydropiper and the coptis chinensis are extracted, the abundance of probiotics such as lactobacillus and Acermanni are obviously up-regulated, the abundance of harmful microbiota such as bacillus prismatic, molluscum and the like is obviously down-regulated, and the metabolite levels including tyrosine and steroid hormone are regulated.
Description
Technical Field
The invention relates to the field of traditional Chinese medicine compositions for resisting oxidation and regulating intestinal flora, in particular to a preparation method of a traditional Chinese medicine composition for resisting oxidation and regulating intestinal flora.
Background
The dynamic balance of intestinal microorganisms is closely related to human health, and intestinal microbiota can regulate gastrointestinal homeostasis, host metabolism and immune system, and development of various diseases. Intestinal microbiota dysregulation and altered metabolic phenotype are closely related to the pathophysiology of various diseases, such as GUs and Inflammatory Bowel Disease (IBD), among others. The traditional Chinese medicine or medicated diet has beneficial effects in maintaining intestinal function integrity and relieving mucosa injury by regulating intestinal dysbacteriosis. Various compounds contained in the traditional Chinese medicine inevitably interact with intestinal microbiota after oral administration, and the stable state of the intestinal microbiota is restored by regulating the community structure and metabolism of the intestinal microbiota, and pathological and clinical symptoms are relieved, so that the treatment effect is achieved. Meanwhile, the intestinal microbiota can metabolize or convert active substances of the traditional Chinese medicine, so that the curative effect of the traditional Chinese medicine is changed, the damage of toxic components to the body is weakened, adverse reactions of the medicine to the body are avoided, and the traditional Chinese medicine plays a better role in preventing and treating diseases.
Different intestinal microorganisms have different effects on host health. Lactobacillus and Acremonium belong to the beneficial bacteria. The lactobacillus has effects in relieving inflammation, preventing pathogen invasion and clostridium difficile infection, activating phagocytosis of macrophage, and enhancing immunity. Pharmacological actions of Ackermana include alleviating intestinal inflammation, delaying aging, reducing blood lipid and blood glucose, enhancing immunity, regulating nervous system function, and anti-inflammatory and anticancer effects. The mechanism of action is to improve the thickness of intestinal mucus, maintain the integrity of the intestinal barrier, and prevent invasion of foreign pathogens or toxic substances. Traditional Chinese medicine plays a key role in a variety of diseases by targeting intestinal flora. Lactobacillus and AKK bacteria may be one of the main targets of traditional Chinese medicine, and significant increase in AKK bacteria abundance after treatment with traditional Chinese medicine is a strong evidence that may suggest that excessive lactobacillus and akmann bacteria may have beneficial effects on physical health.
Disclosure of Invention
Accordingly, the present invention provides a preparation method for antioxidant and intestinal flora regulation, which solves the above problems.
The technical scheme of the invention is realized as follows:
a Chinese medicinal composition for resisting oxidation and regulating intestinal flora comprises herba Polygoni Hydropiperis and Coptidis rhizoma at a mass ratio of 1.8-2.2:1.
Further, the preparation method of the traditional Chinese medicine composition for resisting oxidization and regulating intestinal flora comprises the following steps:
(1) Drying and pulverizing herba Polygoni Hydropiperis, processing herba Polygoni Capitati powder by distillation, soaking distilled herba Polygoni Capitati powder in ethanol solution to obtain extractive solution, and concentrating to obtain herba Polygoni Capitati extract;
(2) Extracting the polygonum hydropiper extract by petroleum ether and ethyl acetate in sequence to obtain an ethyl acetate part;
(3) Adsorbing the ethyl acetate part by macroporous resin, and eluting with ethanol solvent to obtain the effective part of herba Polygoni Hydropiperis;
(4) Pulverizing Coptidis rhizoma to obtain Coptidis rhizoma powder, and extracting Coptidis rhizoma powder with subcritical water to obtain Coptidis rhizoma extractive solution;
(5) Adsorbing Coptidis rhizoma extractive solution with macroporous resin, sequentially eluting with water, 80-90wt% ethanol solution, 50-60deg.C ethanol solution and 10-20wt% ethanol solution, collecting eluate, and drying to obtain Coptidis rhizoma effective component.
Further, in the step (1), the distillation temperature of the distillation method is 55-65 ℃ and the distillation time is 30-40min.
Further, in the step (1), the mass ratio of the polygonum hydropiper powder to the ethanol solution is 1:8-10, the soaking time is 15-18h, the soaking times are 2-3 times, the concentration of the ethanol solution is 75-85wt%, and the concentration is carried out until the water content is 30-32%.
Further, in the step (2), the mass ratio of the polygonum hydropiper extract to the petroleum ether to the ethyl acetate is 1:3-5:8-10.
Further, in the step (3), the weight ratio of the coptis extract to the macroporous resin is 1:5-10, and the coptis extract and the macroporous resin are eluted by ethanol solution with the volume of 3-5 times of the column volume, wherein the concentration of the ethanol solution is 30-90wt%.
Further, in the step (4), the subcritical water temperature is 150-170 ℃, the extraction pressure is 10-13MPa, the flow rate is 15-18L/h, and the extraction time is 140-160min.
Further, in the step (5), the mass ratio of the coptis extract to the macroporous resin is 1:7-9, the water consumption is 3-5 times of the column volume, the ethanol solution with the concentration of 80-90wt% is 7-9 times of the column volume, the ethanol solution with the concentration of 50-60wt% is 1-2 times of the column volume, and the ethanol solution with the concentration of 10-20wt% is 3-4 times of the column volume.
Further, in the step (3), the type of the macroporous resin is AB-8, and in the step (5), the type of the macroporous resin is polystyrene type macroporous resin.
The invention has the beneficial effects that:
the Chinese medicine extract consists of the polygonum hydropiper and the coptis chinensis, the specific extraction method is adopted to extract the effective components in the polygonum hydropiper and the coptis chinensis, the structure and the composition of intestinal microbiota are obviously changed after the polygonum hydropiper and the coptis chinensis extract are used, the abundance of probiotics such as lactobacillus and Acermannin are obviously up-regulated, the abundance of harmful microbiota such as bacillus prismatic, mollis and the like is obviously down-regulated, and the metabolite level including tyrosine and steroid hormone is regulated.
Pharmacodynamics research shows that the composition has obvious effect of improving intestinal flora disorder, and can raise the expression of antioxidant enzyme and strengthen antioxidant capacity.
Drawings
FIG. 1A comparison of SOD activities
FIG. 2 influence of example 1 composition on intestinal microbiologic diversity
FIG. 3 influence of example 1 composition on intestinal microbiota composition
FIGS. 4-6 Effect of example 1 compositions the present compositions on intestinal microflora
FIG. 7 Effect of example 1 composition on Lactobacillus entericus composition and abundance
FIG. 8 influence of important metabolic pathways and differential metabolites of the composition of example 1
FIG. 9 comparison of the effects of example 1 compositions on normal GES-1 cell proliferation
FIG. 10 example 1 composition pair H 2 O 2 Induction of GES-1 cell damage effects
Detailed Description
In order to better understand the technical content of the present invention, the following provides specific examples to further illustrate the present invention.
Example 1
Weighing the polygonum hydropiper and the coptis chinensis with the mass ratio of 2:1.
(1) Drying and pulverizing herba Polygoni Hydropiperis whole herb to obtain herba Polygoni Capitati powder, distilling herba Polygoni Capitati powder at 55-65deg.C for 30-40min, soaking in 75-85wt% ethanol solution for 15-18 hr for 2-3 times to obtain extractive solution, and concentrating until the water content is 30-32% to obtain herba Polygoni Capitati extract;
(2) Extracting the polygonum hydropiper extract by petroleum ether and ethyl acetate in sequence, wherein the mass ratio of the polygonum hydropiper extract to the petroleum ether to the ethyl acetate is 1:3-5:8-10, and obtaining an ethyl acetate part;
(3) Adsorbing the ethyl acetate part by using AB-8 macroporous resin, eluting with 3-5 times of 60wt% ethanol solution with the concentration of column volume to obtain the effective part of herba Polygoni Hydropiperis with the weight ratio of Coptidis rhizoma extract to HPD-100 macroporous resin of 1:5-10;
(4) Pulverizing Coptidis rhizoma to obtain Coptidis rhizoma powder, extracting Coptidis rhizoma powder with subcritical water as solvent at 150-170deg.C under 10-13MPa and flow rate of 15-18L/h for 140-160min to obtain Coptidis rhizoma extractive solution;
(5) Adsorbing the coptis chinensis extract by using polystyrene macroporous resin, wherein the mass ratio of the coptis chinensis extract to the polystyrene macroporous resin is 1:8, sequentially adopting 4 times of column volume of water, 8 times of column volume of ethanol solution with the concentration of 85wt%, 1.5 times of column volume of ethanol solution with the concentration of 55wt%, and 3.5 times of column volume of ethanol solution with the concentration of 15wt% to perform elution, collecting eluent, and drying to obtain the coptis chinensis effective part.
(6) Combining the effective parts of herba Polygoni Hydropiperis and Coptidis rhizoma to obtain the final product.
Test example 1
The invention tests that the intestinal flora disorder is induced by constraint water immersion stress
1. Test materials:
reagent:
pro Kit, (QIAGEN, USA); fastpfu DNA Polymerase (TransGen, china); axyPrepDNA gel recovery kit (Axygen, USA); NEXTFLEX. Rapid DNA-Seq Kit (Bioo Scientific, USA); miSeq Reagent Kit v3 (Illumina, U.S.A.)
Instrument: an analytical electronic balance (Sartorius cerdolis, germany); cryo-mill (Retsch leichi, germany); cryogenic centrifuges (Eppendorf Ai Bende, germany); vortex mixer (Crystal essence Qi in U.S.); PCR instrument (ABI)
Model 9700); sequencer (Illumina Miseq, usa).
2. The test method comprises the following steps:
SD rats were randomly divided into 3 groups: normal group, model group, present composition group, 10 per group. Distilled water is given to the normal group and the model group, and the administration group is administered for 1 time a day for 6 days continuously; before molding, the rats are fasted without water inhibition for 24 hours, after the last administration, the rats except the normal group are placed into a self-made rat cage, the head faces upwards, limbs are fixed, then the rat cage is vertically immersed into a constant-temperature water tank (19+/-1 ℃), the water level reaches the xiphoid process position of the rats, and the molding is finished after the last 7 hours. After the molding, the abdominal cavity is anesthetized with 10% chloral hydrate, the abdominal aorta is collected with blood sample, and the blood serum is collected by centrifugation. Then, 3 faeces are taken from the colon, put into liquid nitrogen and then transferred to-80 ℃ for preservation.
Serum SOD activity assay: firstly, carrying out a small sample pre-experiment, diluting serum stock solution to 5-10 times by using normal saline, completing all experimental operations according to the instruction of a SOD assay (WST-1 method) kit, detecting the OD value of a micro-pore plate, calculating the SOD inhibition rate, analyzing the optimal dilution ratio of samples, controlling the SOD inhibition rate of each group of samples to be between 40 and 60 percent as much as possible, and then carrying out a large amount of formal experiments, wherein the calculation method refers to the instruction.
Sequencing experiment procedure: total DNA extraction and detection, PCR amplification, PCR product identification, purification and quantification, PE library construction and Illumina sequencing.
Bioinformatics analysis: PE reads obtained by Miseq sequencing are spliced according to an overlap relation, quality control and filtering are carried out on sequence quality, and OTU cluster analysis and species taxonomy analysis are carried out after samples are distinguished. Based on the OTU cluster analysis result, various diversity index analyses can be performed, and the sequencing depth is detected; based on the taxonomic information, statistics of the community structure can be performed at various classification levels. Based on the analysis, a series of deep statistical and visual analysis of community structure, phylogenetic development and the like can be performed.
3. Experimental results
1. Referring to fig. 1, the SOD results show that the SOD activity of the model group is significantly reduced compared with that of the normal group, and the SOD activity (P < 0.01) can be significantly improved after pretreatment of the composition of the invention compared with the model group.
2. The effective components in the coptis chinensis and polygonum hydropiper extracts in the invention have influence on the diversity of intestinal microorganisms: alpha diversity analysis was performed on the 16S rRNA sequencing results based on a 97% similarity level. Statistical analysis of the alpha diversity index shows that the diversity of the model group is not different from that of the control group, and shows that the influence of stress stimulation on the diversity of intestinal microorganisms is small, and the composition treatment obviously increases the diversity of intestinal microbial communities. As the number of sampling sequences increases, the sparse curve tends to flatten, indicating enough information for sequencing depth to cover most microbial species, and the results are shown in fig. 2.
3. In the invention, the effective components in the coptis chinensis and polygonum hydropiper extracts have influence on the intestinal microbial composition: the PLS-DA is used for analyzing the composition profile of intestinal microbiota among the model group, the control group and the composition group, and the effect of the effective components in the coptis chinensis and polygonum hydropiper extracts on the intestinal microbiota structure. As shown in fig. 3, the model group and the control group are completely separated and distributed in different quadrants, and there is a significant difference, which indicates that stress causes a significant change in the structure of the intestinal microbiota of the rat, while the treatment group of the composition is completely separated from the model group, which indicates that the composition shows a significant effect on the structure of the intestinal microbiota.
4. In the invention, the effective components in the coptis chinensis and polygonum hydropiper extracts have influence on intestinal microflora: the composition treatment changes at the genus level of intestinal microorganisms more significantly than the portal level. At the phylum level, the composition of dominant bacteria in each group is substantially similar, with the two dominant phylum being the firmicutes phylum and the bacteroides phylum. Verrucomicrobiota abundance was significantly reduced in the model group compared to the normal group, whereas Verrucomicrobiota abundance was reversed after treatment with the present composition, and firmicutes abundance was significantly increased compared to the model group. At the genus level, the highest relative abundance of 5 genera in the three groups were lactobacillus, romidepsia, norank_f __ Muribaculaceae, alloprevotella and Akkermansia, respectively. The abundance of lactobacillus and ackermanni in the model group was significantly reduced compared to the normal group, while the abundance of clostridium_ucg-014 and eubacterium_co-pro-stances was increased. The abundance of lactobacillus and ackermannia is significantly increased after the treatment of the present composition, while the abundance of clostridium_ucg-014 and eubacterium_co-pro stanols is significantly decreased. These reactions show that the effective components in the coptis chinensis and polygonum hydropiper extracts have obvious regulation effect on intestinal microbiota in the invention, and are shown in figures 4-6.
5. Effect of the present composition on the composition and abundance of lactobacillus in the intestinal tract: further analysis of the composition and variation of Lactobacillus in intestinal microorganisms showed that the composition had a significant effect on Lactobacillus and that the abundance of Lactobacillus after treatment with the composition increased significantly, mainly including Lactobacillus murinus, lacillus intestinalis, lacobacillus johnsonii, lactobacillus reuteri, gun_metal_g __ Lactobacillus, uncultured _bacterium_g __ Lactobacillus and unclassified_g __ Lactobacillus. The effective components in the coptis chinensis and polygonum hydropiper extracts in the invention can obviously reverse stress-induced intestinal microbial disorder of rats, and are shown in figure 7.
6. The effect of active ingredients in coptis chinensis and polygonum hydropiper extracts on important metabolic pathways and differential metabolites in the invention: there are two important metabolic pathways, tyrosine metabolism and steroid hormone biosynthesis. The metabolic products of these two metabolic pathways are significantly different from each other, including tyrosine metabolites such as L-tyrosine and L-dopa, and steroid hormone biosynthesis substances such as 21-deoxycortisol, dihydrocortisol, and tetrahydrocortisone. The composition can reduce L-tyrosine and L-dopa levels and 21-deoxycortisol, dihydrocortisol and tetrahydrocortisol levels, thereby improving tyrosine metabolism and HPA axis disorder, as shown in figure 8.
7. Analysis of the correlation of intestinal microbiota with fecal metabolites: at the genus level, the abundance changes of Acremonium and Lactobacillus are inversely related to the changes of tyrosine, 21-hydroxy pregnenolone, D-galactose and cholic acid. These differential metabolites are key fecal metabolites that regulate ackermanni and lactobacillus. The effective components in the coptis chinensis and polygonum hydropiper extracts regulate the changes of fecal metabolites by improving the intestinal microflora composition.
Experimental example 2 cell experiment
1. Effect on normal GES-1 cell proliferation
Taking GES-1 cells in logarithmic growth phase, adding 0.25% trypsin 1mL, digesting at room temperature for 1min, adding 1640 culture solution to terminate digestion, and preparing into concentration of 2×10 5 Inoculating single cell suspension of each/mL on 48-well plate according to cell solution of 100 μL/well, respectively adding composition of example 1 (low concentration 0.5mg/mL, medium concentration 1mg/mL, high concentration 5 mg/mL) of different concentrations after cell adhesion, arranging 6 parallel compound wells for each group of samples, arranging model control group and blank control group, and setting 37 ℃ and 5% CO 2 After 24h of incubation, the stock solution was discarded, 10ul of CC-K8 reagent and 90ul of medium were added to each well, and after 3h of incubation, the absorbance was measured at 450nm using an ELISA reader. Cell viability was determined by CCK-8 method.
2. For H 2 O 2 Induction of GES-1 cell damage effects
Taking GES-1 cells in logarithmic growth phase, adding 0.25% trypsin 1mL, digesting at room temperature for 1min, adding 1640 culture solution to terminate digestion, and preparing into concentration of 2×10 5 individual/mL monolithsInoculating cell suspension into 96-well plate at cell solution of 100 μl/well, adding extract after cell adhesion, arranging 6 parallel multiple wells for each group of samples, arranging negative control group and blank group without cells, and adding 5% CO at 37deg.C 2 After culturing for 24H, the stock solution is discarded, and 200uM H is added 2 O 2 After 4h of injury, the culture broth was aspirated, 10ul of CC-K8 reagent and 90ul of medium were added to each well, and after 3h of incubation, the absorbance was measured at 450nm using an ELISA reader.
Referring to FIG. 9, the traditional Chinese medicine composition prepared in example 1 has different concentrations capable of obviously promoting normal GES-1 cell proliferation and has obvious dose-dependent relationship.
Referring to FIG. 10, GES-1 cells were subjected to 200uM H 2 O 2 After 4 hours of induced injury, the cell survival rate of the model group is obviously reduced compared with that of the normal group; compared with the model group, the compositions of the invention can obviously improve the cell survival rate (p after pretreatment for 12 hours at low and high doses<0.05)。
The foregoing description of the preferred embodiments of the invention is not intended to be limiting, but rather is intended to cover all modifications, equivalents, alternatives, and improvements that fall within the spirit and scope of the invention.
Claims (9)
1. A traditional Chinese medicine composition for resisting oxidization and regulating intestinal flora is characterized by comprising polygonum hydropiper and coptis chinensis in a mass ratio of 1.8-2.2:1.
2. The method for preparing the traditional Chinese medicine composition for resisting oxidation and regulating intestinal flora according to claim 1, comprising the following steps:
(1) Drying and pulverizing herba Polygoni Hydropiperis, processing herba Polygoni Capitati powder by distillation, soaking distilled herba Polygoni Capitati powder in ethanol solution to obtain extractive solution, and concentrating to obtain herba Polygoni Capitati extract;
(2) Extracting the polygonum hydropiper extract by petroleum ether and ethyl acetate in sequence to obtain an ethyl acetate part;
(3) Adsorbing the ethyl acetate part by macroporous resin, and eluting with ethanol solvent to obtain the effective part of herba Polygoni Hydropiperis;
(4) Pulverizing Coptidis rhizoma to obtain Coptidis rhizoma powder, and extracting Coptidis rhizoma powder with subcritical water to obtain Coptidis rhizoma extractive solution;
(5) Adsorbing Coptidis rhizoma extractive solution with macroporous resin, sequentially eluting with water, 80-90wt% ethanol solution, 50-60deg.C ethanol solution and 10-20wt% ethanol solution, collecting eluate, and drying to obtain Coptidis rhizoma effective component.
3. The method for preparing an antioxidant and intestinal flora-regulating Chinese medicinal composition according to claim 2, wherein in the step (1), the distillation temperature is 55-65deg.C, and the distillation time is 30-40min.
4. The method for preparing the traditional Chinese medicine composition for resisting oxidation and regulating intestinal flora according to claim 2, wherein in the step (1), the mass ratio of the polygonum hydropiper powder to the ethanol solution is 1:8-10, the soaking time is 15-18h, the soaking times are 2-3 times, the concentration of the ethanol solution is 75-85wt%, and the concentration is 30-32%.
5. The method for preparing the traditional Chinese medicine composition for resisting oxidation and regulating intestinal flora according to claim 2, wherein in the step (2), the mass ratio of the polygonum hydropiper extract to the petroleum ether to the ethyl acetate is 1:3-5:8-10.
6. The method for preparing the traditional Chinese medicine composition for resisting oxidation and regulating intestinal flora according to claim 2, wherein in the step (3), the weight ratio of the coptis extract to the macroporous resin is 1:5-10, the coptis extract and the macroporous resin are eluted by ethanol solution with the volume of 3-5 times of the column volume, and the concentration of the ethanol solution is 30-90wt%.
7. The method for preparing an antioxidant and intestinal flora-regulating Chinese medicinal composition according to claim 2, wherein in the step (4), the subcritical water temperature is 150-170 ℃, the extraction pressure is 10-13MPa, the flow rate is 15-18L/h, and the extraction time is 140-160min.
8. The method for preparing the traditional Chinese medicine composition for resisting oxidation and regulating intestinal flora according to claim 2, wherein in the step (5), the mass ratio of the coptis chinensis extracting solution to the macroporous resin is 1:7-9, the water consumption is 3-5 times of column volume, the ethanol solution with the concentration of 80-90wt% is 7-9 times of column volume, the ethanol solution with the concentration of 50-60wt% is 1-2 times of column volume, and the ethanol solution with the concentration of 10-20wt% is 3-4 times of column volume.
9. The method for preparing the traditional Chinese medicine composition for resisting oxidation and regulating intestinal flora according to claim 2, wherein in the step (3), the type of the macroporous resin is AB-8, and in the step (5), the type of the macroporous resin is polystyrene type macroporous resin.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310493293.0A CN116327830B (en) | 2023-05-04 | 2023-05-04 | Traditional Chinese medicine composition for resisting oxidization and regulating intestinal flora and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310493293.0A CN116327830B (en) | 2023-05-04 | 2023-05-04 | Traditional Chinese medicine composition for resisting oxidization and regulating intestinal flora and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116327830A true CN116327830A (en) | 2023-06-27 |
| CN116327830B CN116327830B (en) | 2024-04-12 |
Family
ID=86878945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310493293.0A Active CN116327830B (en) | 2023-05-04 | 2023-05-04 | Traditional Chinese medicine composition for resisting oxidization and regulating intestinal flora and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116327830B (en) |
Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001022934A2 (en) * | 1999-09-24 | 2001-04-05 | Yng Wong Quing Non | Delivery of small doses of ingestible treatments |
| WO2012094834A1 (en) * | 2011-01-14 | 2012-07-19 | 广东药学院 | Compound traditional chinese medicine extract for prevention and treatment of glycometabolism disorders and preparation method thereof |
| CN104138442A (en) * | 2014-07-19 | 2014-11-12 | 扬中牧乐药业有限公司 | Compound Chinese herbal medicine extracting solution preventing and treating sea eel bacterial enteritis and preparing method of compound Chinese herbal medicine extracting solution |
| CN108969584A (en) * | 2018-10-24 | 2018-12-11 | 海南医学院 | A kind of composition and its preparation method and application |
| CN110279764A (en) * | 2019-07-16 | 2019-09-27 | 广西富凤农牧集团有限公司 | A kind of fermented tcm additive and preparation method thereof improving poultry intestinal tract health |
| CN111821311A (en) * | 2019-04-18 | 2020-10-27 | 中国医学科学院药物研究所 | Application of berberine hydrochloride and stachyose composition in regulating intestinal flora |
| CN113975317A (en) * | 2021-11-22 | 2022-01-28 | 美益添生物医药(武汉)有限公司 | Application of coptis chinensis in preparation of product for promoting proliferation of beneficial bacteria in intestinal tract |
-
2023
- 2023-05-04 CN CN202310493293.0A patent/CN116327830B/en active Active
Patent Citations (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001022934A2 (en) * | 1999-09-24 | 2001-04-05 | Yng Wong Quing Non | Delivery of small doses of ingestible treatments |
| WO2012094834A1 (en) * | 2011-01-14 | 2012-07-19 | 广东药学院 | Compound traditional chinese medicine extract for prevention and treatment of glycometabolism disorders and preparation method thereof |
| CN104138442A (en) * | 2014-07-19 | 2014-11-12 | 扬中牧乐药业有限公司 | Compound Chinese herbal medicine extracting solution preventing and treating sea eel bacterial enteritis and preparing method of compound Chinese herbal medicine extracting solution |
| CN108969584A (en) * | 2018-10-24 | 2018-12-11 | 海南医学院 | A kind of composition and its preparation method and application |
| CN111821311A (en) * | 2019-04-18 | 2020-10-27 | 中国医学科学院药物研究所 | Application of berberine hydrochloride and stachyose composition in regulating intestinal flora |
| CN110279764A (en) * | 2019-07-16 | 2019-09-27 | 广西富凤农牧集团有限公司 | A kind of fermented tcm additive and preparation method thereof improving poultry intestinal tract health |
| CN113975317A (en) * | 2021-11-22 | 2022-01-28 | 美益添生物医药(武汉)有限公司 | Application of coptis chinensis in preparation of product for promoting proliferation of beneficial bacteria in intestinal tract |
Non-Patent Citations (4)
| Title |
|---|
| SHOUZHONG REN;等: "Polygonum hydropiper extract attenuates ethanolinduced gastric damage through antioxidant and antiinflammatory pathways", BRAZILIAN JOURNAL OF MEDICAL AND BIOLOGICAL RESEARCH, vol. 54, no. 08, pages 1 - 9 * |
| 任守忠;等: "枫蓼提取物抗炎、止泻作用的物质基础研究", 时珍国医国药, vol. 27, no. 01, 20 January 2016 (2016-01-20), pages 32 - 34 * |
| 杨卫丽;曾祥周;张俊清;任守忠;陈峰;刘明生;: "牛耳枫与辣蓼提取物药效学研究", 时珍国医国药, vol. 19, no. 09, pages 2229 - 2231 * |
| 聂敏仁, 等: "中西医结合治疗观赏犬细小病毒病", 河南畜牧兽医, vol. 15, no. 01, pages 1 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116327830B (en) | 2024-04-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114507621B (en) | Lactobacillus plantarum and application thereof in reducing uric acid, weight and inflammation | |
| CN113209177B (en) | Method for extracting flavonoid compounds in citrus peels with assistance of ultrasonic waves | |
| Yi et al. | Lactobacillus plantarum CQPC02-fermented soybean milk improves loperamide-induced constipation in mice | |
| AU2020101537A4 (en) | A kind of probiotic and application thereof in gastric injury | |
| CN113549582B (en) | Licorice fermentation liquor with effects of resisting oxidation, relieving acute alcoholic liver injury and regulating intestinal flora and application thereof | |
| CN116445346B (en) | Lactobacillus reuteri for improving polycystic ovary syndrome and application thereof | |
| CN111569007A (en) | Probiotic traditional Chinese medicine co-culture extracting solution, preparation method and application | |
| CN114634899B (en) | Lactobacillus fermentum and application thereof | |
| CN115287239A (en) | Lactobacillus plantarum capable of degrading nucleosides and purines in vitro and reducing uric acid and application thereof | |
| Wang et al. | Effects of Scutellaria baicalensis Georgi. on intestinal flora in rats with spleen deficiency and damp-heat | |
| CN110771875A (en) | Method for fermenting ginseng by using lactobacillus | |
| CN116327830B (en) | Traditional Chinese medicine composition for resisting oxidization and regulating intestinal flora and preparation method thereof | |
| WO2021109879A1 (en) | Composition having wholesome personalized intestinal flora diversity function and application | |
| CN111560447A (en) | Method for evaluating regulation capacity of hericium erinaceus beta-glucan on intestinal flora | |
| CN116355804A (en) | Lactobacillus reuteri for treating polycystic ovary syndrome and application thereof | |
| WO2008064521A1 (en) | Lactobacillus fermentum cms-h002 and use thereof | |
| Liu et al. | Intestinal bacteria are involved in radix glycyrrhizae and radix euphorbiae pekinensis incompatibility | |
| CN114869916A (en) | Lactobacillus plantarum metazoan and application thereof in intestinal microecology modification and cholesterol reduction products | |
| CN114717161A (en) | Lactobacillus fermentum and application thereof | |
| CN118028190B (en) | Lactobacillus mucilaginosus BAS313 and application thereof in preparation of hypoglycemic products | |
| CN116836872B (en) | Bacillus subtilis polysaccharide alpha-amylase inhibitor and application thereof | |
| CN117866850B (en) | Lactobacillus plantarum and application thereof in platycodon grandiflorum fermentation | |
| CN113546117B (en) | Preparation method for improving content of geniposide | |
| CN117965401B (en) | Lactobacillus rhamnosus AFY01 and application of product thereof in inflammatory colon cancer | |
| CN110123824A (en) | Ilexsaponin A1New application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |